Patents by Inventor Lieven Meerpoel

Lieven Meerpoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190337924
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1a, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 7, 2019
    Inventors: Gilles Bignan, Peter J Connolly, Jan Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar
  • Patent number: 10464939
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 5, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Publication number: 20190330190
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 31, 2019
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • Publication number: 20190263833
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 29, 2019
    Inventors: Tongfei WU, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Edward Charles LAWSON, Lieven MEERPOEL, Vineet PANDE, Marcus Cornelis Bernardus Catharina PARADÉ, Wim Bert Griet SCHEPENS, Weimei SUN, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE
  • Publication number: 20190263804
    Abstract: The present invention relates to azabenzimidazole derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: June 15, 2017
    Publication date: August 29, 2019
    Inventors: Isabelle Noelle Constance Pilatte, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquier, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Didier Jean-Claude Berthelot
  • Publication number: 20190169199
    Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: June 15, 2017
    Publication date: June 6, 2019
    Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Birgine Sophie Poncelet, Olivier Alexis Georges Querolle
  • Patent number: 10280170
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: May 7, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Meerpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • Publication number: 20190119299
    Abstract: Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)-cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: April 25, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Publication number: 20190062311
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 28, 2019
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Patent number: 10202387
    Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 12, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Publication number: 20190031670
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: January 31, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannnis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Patent number: 10138246
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: November 27, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannnis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Publication number: 20180327401
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Application
    Filed: July 19, 2018
    Publication date: November 15, 2018
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Publication number: 20180298021
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • Patent number: 10087187
    Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Patent number: 10077261
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 18, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Publication number: 20180243328
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Johannes Wilhelmus John F Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Patent number: 10052320
    Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: August 21, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Steven John Woodhead, Christopher William Murray, Valerio Berdini, Gordon Saxty, Gilbert Ebai Besong, Lieven Meerpoel, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • Patent number: 10045982
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 14, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • Patent number: 10017509
    Abstract: The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: July 10, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gaston Stanislas Marcella Diels, Bruno Schoentjes, Matthias Luc Aime Versele, Didier Jean-Claude Berthelot, Marc Willems, Marcel Viellevoye, Werner Constant Johan Embrechts, Berthold Wroblowski, Lieven Meerpoel